Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  icotinib hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-7 of 7 for your search:
Start Over
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV01, NCT01465243
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Phase: Phase IV
Type: Treatment
Status: Closed
Age: 70 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV20, NCT01646450
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Phase: Phase IV
Type: Treatment
Status: Temporarily closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV41, NCT01720901
Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV36, NCT01719536
Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV04, NCT01516983
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 75
Sponsor: Other
Protocol IDs: ZhejiangCH-LCBM-1201, NCT01514877
Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: BD-IC-IV70, NCT02278458
Start Over